➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Moodys
Dow
Express Scripts

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 213674

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 213674 describes XTANDI, which is a drug marketed by Astellas and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the XTANDI profile page.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the enzalutamide profile page.
Summary for 213674
Tradename:XTANDI
Applicant:Astellas
Ingredient:enzalutamide
Patents:3
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 213674
Generic Entry Date for 213674*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 213674
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XTANDI enzalutamide TABLET;ORAL 213674 NDA Astellas Pharma US, Inc. 0469-0625 0469-0625-99 1 BOTTLE in 1 CARTON (0469-0625-99) > 120 TABLET in 1 BOTTLE
XTANDI enzalutamide TABLET;ORAL 213674 NDA Astellas Pharma US, Inc. 0469-0725 0469-0725-60 1 BOTTLE in 1 CARTON (0469-0725-60) > 60 TABLET in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Aug 4, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 16, 2022
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Jul 13, 2021
Regulatory Exclusivity Use:
Patent:  Get Started for $10Patent Expiration:Aug 13, 2027Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Merck
Express Scripts
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.